Add-on Services for IVF – The Evidence

In vitro fertilization already asks a lot from people: time, money, hope, injections, calendar math, and the ability to stay calm while someone says, “Just relax.” Then come the IVF add-ons: extra tests, lab techniques, medications, procedures, supplements, and technologies that may be offered alongside a standard IVF cycle. Some sound wonderfully scientific. Some sound like they were named by a marketing department that had too much coffee. And nearly all arrive at the same emotionally loaded moment: when patients want to do everything possible to improve their chance of having a baby.

The big question is not whether IVF add-on services sound promising. Many do. The better question is: What evidence shows that this add-on improves live birth rates for someone like you? In fertility care, the most meaningful outcome is not just a better-looking embryo, a thicker report, or a reassuring graph. The finish line is usually a healthy singleton live birth, achieved as safely and efficiently as possible.

This article reviews the evidence behind common IVF add-ons, including preimplantation genetic testing for aneuploidy, assisted hatching, embryo glue, time-lapse imaging, endometrial scratching, ERA testing, immunotherapy, acupuncture, supplements, and emerging “rejuvenation” treatments. The goal is not to scare you away from every extra option. It is to help you walk into the clinic with clearer questions, steadier expectations, and a wallet that does not faint in the parking lot.

What Are IVF Add-on Services?

IVF add-ons are optional services offered in addition to standard fertility treatment. They may be used in the laboratory, before embryo transfer, during ovarian stimulation, after transfer, or as supportive care. Some are recommended only for specific medical situations. Others are advertised broadly despite limited proof that they improve outcomes for the average IVF patient.

Common IVF add-ons include:

• Preimplantation genetic testing for aneuploidy, often called PGT-A
• Preimplantation genetic testing for monogenic disease or structural rearrangements, known as PGT-M and PGT-SR
• Assisted hatching
• Embryo glue or hyaluronan-enriched transfer medium
• Time-lapse embryo imaging
• Endometrial scratching
• Endometrial receptivity testing, including ERA testing
• Immune treatments such as intralipids, steroids, IVIG, or blood thinners
• Platelet-rich plasma, ovarian PRP, or “ovarian rejuvenation”
• Acupuncture, supplements, and lifestyle-based extras
• Sperm DNA fragmentation testing, PICSI, IMSI, or other sperm-selection methods

Some add-ons are not automatically “bad.” The problem begins when an add-on is sold as a magic upgrade before the evidence has caught up. Fertility medicine is emotionally intense. That makes clear counseling especially important.

How to Judge IVF Add-on Evidence

Not all evidence is equal. A small study showing a higher pregnancy test rate is not the same as a large randomized controlled trial showing a higher live birth rate. A clinic’s success story may be sincere, but it does not prove that the add-on caused the success. In IVF, many variables overlap: age, egg quality, sperm quality, embryo development, uterine factors, lab conditions, transfer technique, and plain biological luck.

The Outcomes That Matter Most

When reviewing IVF add-ons, prioritize these questions:

• Does it improve live birth rate? A positive pregnancy test is exciting, but live birth is the stronger endpoint.
• Does it improve cumulative live birth rate? This means the chance of birth from all embryos created in one egg retrieval, not just one transfer.
• Does it reduce miscarriage? Some add-ons may help select embryos less likely to miscarry, especially in certain age groups.
• Does it reduce time to pregnancy? Faster transfer success can matter emotionally and financially.
• Does it add risk? Even “simple” procedures can carry cost, discomfort, false reassurance, or unintended consequences.
• Is it useful for your diagnosis? Evidence for one group does not automatically apply to everyone.

A helpful rule: if the clinic says, “This may improve your chances,” ask, “For patients with my age, diagnosis, embryo number, and treatment history, what is the evidence for live birth?” That sentence is not rude. It is adult supervision.

PGT-A: Helpful for Some, Not a Universal Upgrade

Preimplantation genetic testing for aneuploidy, or PGT-A, screens embryos for missing or extra chromosomes. Because chromosomal abnormalities become more common with maternal age, PGT-A may help identify embryos with a better chance of implantation and a lower chance of miscarriage in some patients, especially those with several embryos available for testing.

However, PGT-A is not a guaranteed shortcut to a baby. It requires embryo biopsy, freezing in many cases, genetic analysis, and added cost. It may help select which embryo to transfer first, but that does not always mean it improves the total chance of live birth from an entire retrieval. The distinction matters. If three embryos are created and one is labeled euploid, PGT-A may help choose that embryo. But if testing results are uncertain, mosaic, or affected by technical limitations, decision-making can become complicated.

When PGT-A May Be Worth Discussing

PGT-A may be especially worth discussing for patients of advanced reproductive age, those with recurrent pregnancy loss, people who want to reduce the chance of transferring an embryo with a chromosomal abnormality, or patients trying to choose among multiple embryos. It can also support elective single embryo transfer, which helps reduce the risks associated with twins or higher-order multiples.

Still, routine PGT-A for every IVF patient remains debated. Younger patients with few embryos may not always benefit. A patient who produces only one blastocyst, for example, may face a very different risk-benefit calculation than a patient with eight blastocysts. The evidence says PGT-A can be valuable in selected situations, but it should not be treated like the “premium shipping” button on an online order.

PGT-M and PGT-SR: Stronger Reasons in Specific Cases

PGT-M is used when one or both intended parents carry a known single-gene condition, such as cystic fibrosis, sickle cell disease, Huntington disease, or another inherited disorder. PGT-SR is used when a parent has a structural chromosome rearrangement, such as a balanced translocation, that may increase the risk of miscarriage or chromosomally unbalanced embryos.

These tests are different from broad embryo screening. They are not simply add-ons for a vague success boost. They are targeted tools used to reduce the risk of transferring an embryo affected by a known genetic condition or unbalanced chromosome arrangement. For families with a clear genetic indication, these services can be medically meaningful. Counseling with a reproductive endocrinologist and genetic counselor is essential because test setup, accuracy, embryo availability, and ethical considerations all matter.

Assisted Hatching: Logical Idea, Limited Live Birth Proof

Assisted hatching involves creating a small opening in the zona pellucida, the outer shell-like layer around the embryo. The theory is that helping the embryo “hatch” may improve implantation. It sounds sensible, like opening the pickle jar before handing it to someone with slippery hands.

But biology is not always impressed by common sense. Evidence has not shown a clear improvement in live birth rates for routine assisted hatching in fresh IVF cycles. There is also insufficient evidence to recommend it broadly for poor-prognosis patients or frozen embryo transfer cycles. In some situations, assisted hatching is performed because the embryo has already undergone biopsy for genetic testing. But as an extra service sold to improve success, the evidence is modest at best.

Possible risks include embryo damage and a small potential increase in identical twinning. That does not mean assisted hatching is never appropriate. It does mean patients should ask why it is being recommended and whether the clinic’s reason is based on their case or on a default package.

Embryo Glue: Catchy Name, More Nuanced Reality

Embryo glue is not actual glue, which is good news because embryos should not be treated like broken coffee mugs. It usually refers to a transfer medium enriched with hyaluronan, a substance naturally found in the reproductive tract. The idea is that the medium may support embryo attachment to the uterine lining.

Some reviews suggest hyaluronan-enriched transfer media may improve clinical pregnancy or live birth rates in certain settings, but the quality of evidence has not always been strong. Another issue is that improved implantation can increase multiple pregnancy risk if more than one embryo is transferred. In modern IVF, where single embryo transfer is often encouraged, this risk can be managed more safely.

Embryo glue may be one of the more plausible lower-risk add-ons, but it is still not a miracle product. Ask whether your clinic uses it routinely, whether it costs extra, whether it has improved live birth rates in patients like you, and whether single embryo transfer is part of the plan.

Time-Lapse Embryo Imaging: Great Camera, Unclear Baby Boost

Time-lapse imaging allows embryologists to monitor embryo development inside a specialized incubator without repeatedly removing embryos for visual checks. It can generate detailed information about cell division timing and embryo development. From a lab workflow perspective, that can be useful. From a patient perspective, it also sounds impressive. Tiny embryo movie? Science has entered the chat.

The challenge is that better observation does not automatically mean better live birth rates. Current evidence has not clearly shown that time-lapse imaging, with or without embryo-selection algorithms, improves live birth for the general IVF population. It may help laboratories maintain stable culture conditions and collect developmental data, but patients should be cautious when it is marketed as a proven success booster.

If your clinic includes time-lapse imaging at no extra cost, it may be reasonable. If it is a pricey upgrade, ask whether it changes clinical decisions and whether it improves outcomes compared with standard embryo assessment in that clinic.

Endometrial Scratch: A Once-Popular Add-on That Lost Its Shine

Endometrial scratching involves intentionally irritating or lightly injuring the uterine lining before embryo transfer. The theory was that the healing response might make the lining more receptive. For a while, it became a popular IVF add-on, especially after early studies suggested possible benefit.

Larger and better-quality studies have not supported routine use, especially for people undergoing their first IVF cycle. The procedure can be uncomfortable, may add cost, and does not consistently improve live birth rates. For most patients, endometrial scratching is no longer the exciting underdog it once appeared to be. It is more like a sequel that did not live up to the trailer.

There may still be research interest in specific subgroups, such as repeated implantation failure, but routine use should be questioned. If offered, ask what evidence supports it for your exact situation and whether less invasive steps should be considered first.

ERA and Endometrial Receptivity Testing: Personalized, But Not Proven for Everyone

Endometrial receptivity testing, including the ERA test, aims to identify the best timing for embryo transfer by analyzing gene expression in the uterine lining. The concept is appealing: maybe the embryo is fine, but the transfer window is slightly off. Personalized timing sounds elegant, precise, and very 21st century.

However, evidence has not shown that routine endometrial receptivity testing improves outcomes for all IVF patients. Many people will have a receptive result, and changing transfer timing may not improve live birth rates in unselected groups. The test also requires a mock cycle and endometrial biopsy, adding cost and time.

ERA testing may be discussed after repeated failed transfers of good-quality embryos, especially when other factors have been reviewed. But it should not be presented as a universal key that unlocks the uterus. Fertility is complicated; it rarely behaves like a hotel room door.

Immune Treatments: Big Claims, Thin Proof for Routine IVF

Immune-based IVF add-ons include intralipid infusions, intravenous immunoglobulin, steroids, tacrolimus, tumor necrosis factor inhibitors, heparin, aspirin, and other medications intended to calm or modify immune activity. These treatments are sometimes offered to patients with recurrent implantation failure or recurrent pregnancy loss.

The difficulty is that “immune problems” can become a vague umbrella. Without a clear diagnosis, patients may be given powerful treatments with uncertain benefit. Some immune therapies carry real risks, including infection, allergic reactions, medication side effects, bleeding concerns, or complications from suppressing the immune system.

There are situations where blood thinners, aspirin, or immune-related treatment may be medically appropriate, such as certain autoimmune or clotting disorders. But using immune therapy as a routine IVF add-on is not strongly supported by evidence. If this option is raised, ask what condition is being treated, what test confirms it, what live birth data support the treatment, and what risks apply.

PRP, Ovarian Rejuvenation, and Other Emerging Treatments

Platelet-rich plasma, often called PRP, is promoted in some fertility settings for ovarian rejuvenation, thin uterine lining, or repeated implantation failure. The concept is that growth factors from a patient’s own blood may stimulate tissue repair or function. It sounds futuristic, and in medicine, “futuristic” can be either exciting or expensive with better lighting.

At this stage, PRP and ovarian rejuvenation remain experimental for most fertility uses. Evidence is still limited, study designs vary, and standardized protocols are lacking. Patients with diminished ovarian reserve are especially vulnerable to bold claims because time feels urgent. That urgency deserves compassion, not overpromising.

If considering PRP, ask whether it is part of a registered clinical trial, what outcomes are being measured, how safety is monitored, and whether there is published evidence showing improved live birth rates. Experimental does not always mean bad, but it should mean transparent.

Acupuncture and Mind-Body Add-ons: Supportive, Not Guaranteed

Acupuncture is one of the most common complementary therapies used during IVF. Some patients find it relaxing, grounding, and emotionally helpful. Stress reduction matters because IVF can make even calm people feel like they are living inside a spreadsheet with hormones.

However, the evidence that acupuncture improves IVF live birth rates is mixed and generally not strong enough to call it a proven fertility booster. Some studies suggest possible improvements in pregnancy rates, while better-controlled analyses often find no clear difference in live birth when acupuncture is compared with sham acupuncture.

That does not mean acupuncture is useless. If performed by a licensed practitioner using sterile technique, it may be a reasonable supportive choice for stress, comfort, and a sense of control. Just avoid treating it as a replacement for evidence-based fertility care. Also tell your fertility team about any herbs or supplements, because “natural” and “risk-free” are not the same thing.

Supplements: Folic Acid Yes, Miracle Stacks Maybe Not

Fertility supplements are everywhere: CoQ10, DHEA, melatonin, vitamin D, omega-3s, antioxidants, prenatal vitamins, and blends with names that sound like they were designed to make eggs feel glamorous. Some supplements may be reasonable in specific cases. For example, folic acid is recommended before pregnancy to reduce the risk of neural tube defects. Vitamin D may be addressed if a deficiency is documented.

CoQ10 has attracted interest for diminished ovarian reserve and egg quality because it is involved in mitochondrial function. Some studies suggest potential benefits for ovarian response or embryo parameters, but evidence for improved live birth remains less certain. DHEA may be considered in some poor responders, but it can cause side effects and should not be used casually.

The safest approach is boring but wise: bring every supplement bottle to your fertility team, including the ones from the health-food store with a label full of leaves. Ask what dose is appropriate, what benefit is expected, what side effects may occur, and when to stop before retrieval or transfer.

Sperm Add-ons: Testing and Selection Need a Reason

Some IVF add-ons focus on sperm, including sperm DNA fragmentation testing, PICSI, IMSI, microfluidic sperm selection, and antioxidant therapy. These may be marketed to improve embryo quality, fertilization, or miscarriage risk.

Sperm DNA fragmentation testing may be useful in selected situations, such as recurrent pregnancy loss, repeated IVF failure, unexplained infertility, varicocele, smoking exposure, or abnormal semen parameters. But routine testing for everyone is not always necessary. More testing does not automatically mean better treatment.

Advanced sperm-selection methods may help in specific male-factor cases, but evidence varies. Before paying for sperm add-ons, ask whether the result will change the plan. If the answer is “not really,” the test may be more decorative than decisive.

How to Talk to Your Fertility Clinic About Add-ons

A good clinic should welcome thoughtful questions. IVF is not a drive-through window, and add-ons should not be upsold like extra fries. Use the following questions to guide the conversation:

• What problem is this add-on trying to solve in my case?
• Does it improve live birth rate or only laboratory markers?
• What is the evidence for patients my age and with my diagnosis?
• Is this recommended by professional guidelines?
• What are the risks, discomforts, false-positive results, or delays?
• How much does it cost, including follow-up or repeat testing?
• Will it change the treatment plan?
• What happens if I decline it?

The last question is powerful. If declining an add-on does not change your core treatment plan, that tells you something. If the clinic strongly recommends it, they should be able to explain why using evidence, not fog machine language.

The Bottom Line on IVF Add-on Services

IVF add-ons exist on a spectrum. Some are medically important for specific patients, such as PGT-M for a known inherited disease or targeted treatment for a diagnosed medical condition. Some may be reasonable but not essential, such as embryo glue in selected settings. Some are useful for lab monitoring but not proven to increase live birth, such as time-lapse imaging. Others remain weakly supported, experimental, or inappropriate for routine use.

The best IVF care is individualized, evidence-based, and honest about uncertainty. A treatment can be promising without being proven. A test can provide information without improving outcomes. A patient can decline an add-on and still be doing everything responsibly.

Experience-Based Notes: What Patients Often Learn the Hard Way

Many people do not approach IVF add-ons like detached shoppers comparing toaster ovens. They approach them after months or years of disappointment, maybe after a miscarriage, a failed transfer, a bruising diagnosis, or a doctor saying, “Your numbers are not where we want them.” In that moment, an add-on can feel less like an optional service and more like a rope thrown across a canyon.

One common experience is decision fatigue. Patients may start IVF thinking the main choices are simple: clinic, medication plan, retrieval, transfer. Then suddenly they are asked to consider PGT-A, ICSI, assisted hatching, embryo glue, acupuncture, supplements, endometrial testing, immune labs, and whether their embryos should have their own time-lapse documentary. Each choice can feel like a moral test: if you say no, are you giving up? If you say yes, are you being exploited? That emotional pressure is real.

Another common experience is the “one more thing” spiral. After a failed cycle, it is natural to want a new explanation and a new intervention. Doing the exact same plan again can feel unbearable, even when the previous failure may have been due to embryo genetics or chance. Add-ons can provide a sense of action. Sometimes that action is medically useful. Sometimes it is mostly emotional. There is nothing wrong with wanting hope, but hope should come with a receipt, a rationale, and realistic odds.

Patients also learn that clinic language matters. A phrase like “many patients choose this” is not the same as “this has been shown to improve live birth rates for people like you.” A phrase like “it may help implantation” is not the same as “it improves cumulative live birth.” The most empowering habit is to slow down the conversation and ask for absolute numbers. For example: “Out of 100 patients like me, how many more live births would be expected with this add-on?” If the answer is vague, the evidence may be vague too.

Cost is another lived reality. IVF add-ons can quietly turn an already expensive cycle into a financial obstacle course. Patients may feel guilty spending less, especially when future parenthood is at stake. But responsible fertility care should not require buying every extra service. A thoughtful “no” can be just as informed as a thoughtful “yes.”

The most reassuring patient experience often comes from shared decision-making. The best conversations sound like this: “Here is what we know, here is what we do not know, here is why it may or may not apply to you, here is the cost, here are the risks, and here are your alternatives.” That kind of counseling respects both the science and the person sitting across from it.

In the end, IVF add-ons should serve the patient, not the other way around. Evidence does not remove emotion from fertility treatment, but it can keep emotion from being used against you. You deserve hope. You also deserve honesty, clarity, and care that treats your future family as more than a sales funnel with a lab coat.

Conclusion

Add-on services for IVF can be confusing because they live in the gray zone between innovation and marketing. Some have a meaningful role in selected cases. Others remain unproven for routine use. The strongest strategy is not to reject every add-on automatically, but to demand clear evidence, specific reasoning, transparent costs, and honest discussion of risks.

Before agreeing to any IVF add-on, ask whether it improves live birth rates for patients like you, whether it is recommended for your diagnosis, and whether it changes the treatment plan in a meaningful way. Fertility treatment is already difficult enough. You should not have to become a full-time detective just to understand what you are buying.

The evidence-based path is simple, even when the emotions are not: personalize care, avoid unnecessary extras, use proven tools when they apply, and treat promising but unproven options with healthy caution. In IVF, more is not always better. Better is better.